CL2013001914A1 - Metodo para determinar el potencial miopico de un paciente; metodo para diagnosticar la susceptibilidad de un paciente a un trastorno relacionado con la longitud ocular; metodo para tratar un trastorno relacionado con la longitud ocular; y kit. - Google Patents

Metodo para determinar el potencial miopico de un paciente; metodo para diagnosticar la susceptibilidad de un paciente a un trastorno relacionado con la longitud ocular; metodo para tratar un trastorno relacionado con la longitud ocular; y kit.

Info

Publication number
CL2013001914A1
CL2013001914A1 CL2013001914A CL2013001914A CL2013001914A1 CL 2013001914 A1 CL2013001914 A1 CL 2013001914A1 CL 2013001914 A CL2013001914 A CL 2013001914A CL 2013001914 A CL2013001914 A CL 2013001914A CL 2013001914 A1 CL2013001914 A1 CL 2013001914A1
Authority
CL
Chile
Prior art keywords
patient
disorder related
eye length
diagnose
susceptibility
Prior art date
Application number
CL2013001914A
Other languages
English (en)
Inventor
Jay Neitz
Maureen Neitz
Original Assignee
Univ Washington Ct Commerciali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington Ct Commerciali filed Critical Univ Washington Ct Commerciali
Publication of CL2013001914A1 publication Critical patent/CL2013001914A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/398Electrooculography [EOG], e.g. detecting nystagmus; Electroretinography [ERG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C2202/00Generic optical aspects applicable to one or more of the subgroups of G02C7/00
    • G02C2202/24Myopia progression prevention
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/10Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CL2013001914A 2011-01-14 2013-06-28 Metodo para determinar el potencial miopico de un paciente; metodo para diagnosticar la susceptibilidad de un paciente a un trastorno relacionado con la longitud ocular; metodo para tratar un trastorno relacionado con la longitud ocular; y kit. CL2013001914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161432984P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
CL2013001914A1 true CL2013001914A1 (es) 2014-03-07

Family

ID=45562446

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001914A CL2013001914A1 (es) 2011-01-14 2013-06-28 Metodo para determinar el potencial miopico de un paciente; metodo para diagnosticar la susceptibilidad de un paciente a un trastorno relacionado con la longitud ocular; metodo para tratar un trastorno relacionado con la longitud ocular; y kit.

Country Status (17)

Country Link
US (3) US8951729B2 (es)
EP (1) EP2663653B1 (es)
JP (2) JP6141193B2 (es)
KR (1) KR102011947B1 (es)
CN (2) CN103314116B (es)
AR (1) AR084866A1 (es)
AU (1) AU2012205439B2 (es)
BR (1) BR112013017745B1 (es)
CA (1) CA2819250C (es)
CL (1) CL2013001914A1 (es)
CO (1) CO6731117A2 (es)
ES (1) ES2676393T3 (es)
MX (1) MX355606B (es)
RU (1) RU2013137831A (es)
TW (1) TWI631334B (es)
WO (1) WO2012097213A2 (es)
ZA (1) ZA201304334B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552587A1 (en) 2008-12-22 2019-10-16 Medical College of Wisconsin, Inc. Method and apparatus for limiting growth of eye length
RU2013137831A (ru) * 2011-01-14 2015-02-20 Юниверсити Оф Вашингтон Тру Итс Сентер Фор Коммершлайзейшн Способы диагностирования и лечения связанных с длиной глаза нарушений
EP3261525B1 (en) * 2015-02-27 2021-09-29 University Of Washington Methods and reagents for predicting predisposition to refractive error
CA3011794A1 (en) 2016-01-18 2017-07-27 Waveshift Llc Evaluating and reducing myopiagenic effects of electronic displays
US10912456B2 (en) 2016-01-27 2021-02-09 Johnson & Johnson Vision Care, Inc. Ametropia treatment tracking methods and system
US10042181B2 (en) * 2016-01-27 2018-08-07 Johnson & Johnson Vision Care, Inc. Ametropia treatment tracking methods and system
TW202244570A (zh) 2016-08-01 2022-11-16 華盛頓大學 用於治療近視的眼用鏡片
JP6637217B2 (ja) * 2017-03-06 2020-01-29 株式会社坪田ラボ 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法
IL258706A (en) * 2017-04-25 2018-06-28 Johnson & Johnson Vision Care Treatment follow-up methods in emmetropia and system
CN110914743B (zh) 2017-05-08 2021-08-13 视窗视觉公司 用于降低近视的接触镜片及用于制造该接触镜片的方法
EP3495875A1 (en) * 2017-12-06 2019-06-12 Essilor International Method and system for selecting a color filter, optical article comprising such a color filter
US10884264B2 (en) 2018-01-30 2021-01-05 Sightglass Vision, Inc. Ophthalmic lenses with light scattering for treating myopia
WO2020083382A1 (en) * 2018-10-26 2020-04-30 Ai Technologies Inc. Accurate prediction and treatment of myopic progression by artificial intelligence
JP7097845B2 (ja) * 2019-04-23 2022-07-08 ジェネシスヘルスケア株式会社 近視のリスクを判定する方法
KR102396522B1 (ko) 2020-07-28 2022-05-10 가톨릭대학교 산학협력단 안저 후극부의 기하학적 구조를 이용한 병적 근시 판별 방법 및 시스템
EP4006626A1 (en) 2020-11-26 2022-06-01 Carl Zeiss Vision International GmbH Spectacle lens design, spectacle lens kit and method of manufacturing a spectacle lens
AU2022330019A1 (en) * 2021-08-20 2024-03-07 The Johns Hopkins University Photoreceptor cells for retinal and macular repair
WO2023114149A1 (en) * 2021-12-13 2023-06-22 Welch Allyn, Inc. Measurements of keratometry and axial length
WO2023140064A1 (ja) * 2022-01-24 2023-07-27 株式会社ニデック 眼科情報処理装置及び眼科情報処理プログラム

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5837461A (en) * 1996-10-31 1998-11-17 Mcw Research Foundation Detection of cone-photoreceptor-based vision disorders
US6706867B1 (en) * 2000-12-19 2004-03-16 The United States Of America As Represented By The Department Of Health And Human Services DNA array sequence selection
EP1256632A3 (en) * 2001-05-07 2004-01-02 Smithkline Beecham Corporation High throughput polymorphism screening
US20040110179A1 (en) * 2002-03-15 2004-06-10 Shuber Anthony P. Method for alteration detection
US20050208555A1 (en) * 2004-03-16 2005-09-22 Affymetrix, Inc. Methods of genotyping
US7906289B2 (en) * 2008-07-28 2011-03-15 Kaohsiung Medical University Using genetic polymorphisms of the BICD1 gene as a method for diagnosing and treating myopia
EP3552587A1 (en) * 2008-12-22 2019-10-16 Medical College of Wisconsin, Inc. Method and apparatus for limiting growth of eye length
RU2013137831A (ru) * 2011-01-14 2015-02-20 Юниверсити Оф Вашингтон Тру Итс Сентер Фор Коммершлайзейшн Способы диагностирования и лечения связанных с длиной глаза нарушений

Also Published As

Publication number Publication date
AU2012205439A1 (en) 2013-06-06
CN106987628B (zh) 2021-08-06
JP6545738B2 (ja) 2019-07-17
CN103314116B (zh) 2018-04-27
JP2017086092A (ja) 2017-05-25
AU2012205439B2 (en) 2017-03-16
MX355606B (es) 2018-04-24
WO2012097213A2 (en) 2012-07-19
RU2013137831A (ru) 2015-02-20
ES2676393T3 (es) 2018-07-19
MX2013006056A (es) 2014-03-05
US8951729B2 (en) 2015-02-10
KR20140006873A (ko) 2014-01-16
KR102011947B1 (ko) 2019-08-19
EP2663653A2 (en) 2013-11-20
ZA201304334B (en) 2014-12-23
CA2819250C (en) 2020-06-02
JP2014504873A (ja) 2014-02-27
CN106987628A (zh) 2017-07-28
JP6141193B2 (ja) 2017-06-07
US10487361B2 (en) 2019-11-26
CA2819250A1 (en) 2012-07-19
EP2663653B1 (en) 2018-04-11
CN103314116A (zh) 2013-09-18
WO2012097213A3 (en) 2012-10-18
US20150111782A1 (en) 2015-04-23
TW201241429A (en) 2012-10-16
BR112013017745B1 (pt) 2022-01-18
BR112013017745A2 (pt) 2016-08-30
US20120182520A1 (en) 2012-07-19
US20170292160A1 (en) 2017-10-12
CO6731117A2 (es) 2013-08-15
TWI631334B (zh) 2018-08-01
AR084866A1 (es) 2013-07-10

Similar Documents

Publication Publication Date Title
CL2013001914A1 (es) Metodo para determinar el potencial miopico de un paciente; metodo para diagnosticar la susceptibilidad de un paciente a un trastorno relacionado con la longitud ocular; metodo para tratar un trastorno relacionado con la longitud ocular; y kit.
BR112012032948A2 (pt) dispositivos injectores e método de suprimento de solução oftálmica à córnea do olho
IL259775B (en) Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
CL2015000061A1 (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares
BR112012020050A2 (pt) acessório ocular iluminado
BR112013022493A2 (pt) equipamento e método para examinar, diagnosticar ou auxiliar no diagnóstico e no tratamento de problemas funcionais de visão
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
BR112013024169A2 (pt) método para o tratamento e prevenção da doença de parkinson
BRPI0916627A2 (pt) projeto de lente e método para impedir ou retardar a progressão de miopia
HK1201438A1 (en) Treatment of ocular disease
SG11201601286SA (en) Spectacles and method for determining the centre of the pupil of both of the wearer's eyes
ZA201502600B (en) Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
BR112015007758A2 (pt) dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho.
EP3628326C0 (en) METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE
ES2606627T8 (es) Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
HK1186660A1 (en) A water-in-oil type emulsion for treating a disease of the eye
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
IL260078B (en) Therapy used to treat Gaucher disease
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
EP2707486A4 (en) DIAGNOSIS AND TREATMENT OF FRIEDREICH ATAXIA
EP3013425A4 (en) Treatment and diagnosis of ocular disease
FR2993564B1 (fr) Derives d'imidazopyridine utiles dans le traitement du diabete
EP2734221A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM